Voronoi's Largest Shareholder to Participate in Rights Offering with KRW 18 Billion
2023.06.19
⚫ CEO Hyuntae Kim to subscribe to 100% of his allocated shares: "Confident in the clinical success of VRN11"
⚫ Total of KRW 45 billion, 9.98% of existing shares... Accompanied by a bonus issue of 0.2 shares per share
KOSDAQ-listed Voronoi will conduct a KRW 45 billion rights offering to existing shareholders. CEO Hyuntae Kim, the largest shareholder with a stake of approximately 40%, plans to subscribe to 100% of the shares allocated to him in proportion to his shareholding.
Voronoi disclosed that at a board meeting on the 19th it approved resolutions to carry out a paid-in capital increase totaling KRW 45 billion through a rights offering to existing shareholders followed by a public offering of any forfeited shares, and then to conduct a bonus issue of 0.2 shares per share. According to the securities registration statement submitted by Voronoi, approximately 1.29 million shares in total are scheduled to be issued in this rights offering, of which CEO Hyuntae Kim is expected to be allocated approximately 520,000 shares. Based on the expected issue price of KRW 34,950 per share, the new shares allocated to CEO Kim amount to approximately KRW 18 billion.
The shares in this Voronoi rights offering correspond to 9.98% of the total number of shares outstanding. This is a very small volume compared with the fact that, in recent years, many biotech companies have conducted rights offerings equivalent to 20–60% of their outstanding shares. In addition, the discount rate of 15% is lower than the 20–30% discount rates typically applied by biotech companies.
In particular, because CEO Hyuntae Kim, head of the Management Division and the largest shareholder with approximately 40% of Voronoi's shares, will participate by subscribing to 100% of his allocation worth approximately KRW 18 billion, the remaining shares allocated to other shareholders amount to only about KRW 27 billion.
Over the past two years, the share of funds contributed by individual largest shareholders relative to the size of biotech companies' rights offerings has averaged around 2%, with individual largest shareholders' contributions ranging from KRW 400 million to 3.3 billion. A Voronoi representative explained, "Largest shareholder CEO Hyuntae Kim's 100% participation in proportion to his shareholding, his 40% participation rate relative to the size of the offering, and his KRW 18 billion contribution are exceptionally high for an individual largest shareholder, to the point that comparable cases are hard to find among past rights offerings by KOSDAQ-listed companies."
CEO Hyuntae Kim said, "I am confident in the success of our VRN11 pipeline program, a non-small cell lung cancer therapy that will enter global clinical trials in the second half of this year. VRN11 has already secured excellent efficacy and safety data in preclinical efficacy studies and formal GLP toxicity studies, and we have completed without a hitch preparations not only for the global clinical trial aiming for first-in-class status in EGFR C797S lung cancer therapy, but also for expanding global clinical trials as a therapy for EGFR uncommon mutation lung cancer."
Voronoi plans to use the funds raised through this rights offering primarily for the expansion of its own global clinical trials of VRN11, its non-small cell lung cancer therapy.
⚫ Total of KRW 45 billion, 9.98% of existing shares... Accompanied by a bonus issue of 0.2 shares per share
KOSDAQ-listed Voronoi will conduct a KRW 45 billion rights offering to existing shareholders. CEO Hyuntae Kim, the largest shareholder with a stake of approximately 40%, plans to subscribe to 100% of the shares allocated to him in proportion to his shareholding.
Voronoi disclosed that at a board meeting on the 19th it approved resolutions to carry out a paid-in capital increase totaling KRW 45 billion through a rights offering to existing shareholders followed by a public offering of any forfeited shares, and then to conduct a bonus issue of 0.2 shares per share. According to the securities registration statement submitted by Voronoi, approximately 1.29 million shares in total are scheduled to be issued in this rights offering, of which CEO Hyuntae Kim is expected to be allocated approximately 520,000 shares. Based on the expected issue price of KRW 34,950 per share, the new shares allocated to CEO Kim amount to approximately KRW 18 billion.
The shares in this Voronoi rights offering correspond to 9.98% of the total number of shares outstanding. This is a very small volume compared with the fact that, in recent years, many biotech companies have conducted rights offerings equivalent to 20–60% of their outstanding shares. In addition, the discount rate of 15% is lower than the 20–30% discount rates typically applied by biotech companies.
In particular, because CEO Hyuntae Kim, head of the Management Division and the largest shareholder with approximately 40% of Voronoi's shares, will participate by subscribing to 100% of his allocation worth approximately KRW 18 billion, the remaining shares allocated to other shareholders amount to only about KRW 27 billion.
Over the past two years, the share of funds contributed by individual largest shareholders relative to the size of biotech companies' rights offerings has averaged around 2%, with individual largest shareholders' contributions ranging from KRW 400 million to 3.3 billion. A Voronoi representative explained, "Largest shareholder CEO Hyuntae Kim's 100% participation in proportion to his shareholding, his 40% participation rate relative to the size of the offering, and his KRW 18 billion contribution are exceptionally high for an individual largest shareholder, to the point that comparable cases are hard to find among past rights offerings by KOSDAQ-listed companies."
CEO Hyuntae Kim said, "I am confident in the success of our VRN11 pipeline program, a non-small cell lung cancer therapy that will enter global clinical trials in the second half of this year. VRN11 has already secured excellent efficacy and safety data in preclinical efficacy studies and formal GLP toxicity studies, and we have completed without a hitch preparations not only for the global clinical trial aiming for first-in-class status in EGFR C797S lung cancer therapy, but also for expanding global clinical trials as a therapy for EGFR uncommon mutation lung cancer."
Voronoi plans to use the funds raised through this rights offering primarily for the expansion of its own global clinical trials of VRN11, its non-small cell lung cancer therapy.